[go: up one dir, main page]

MX2009009168A - Metodo para activacion de celula t auxiliar y composicion para usarse en el metodo. - Google Patents

Metodo para activacion de celula t auxiliar y composicion para usarse en el metodo.

Info

Publication number
MX2009009168A
MX2009009168A MX2009009168A MX2009009168A MX2009009168A MX 2009009168 A MX2009009168 A MX 2009009168A MX 2009009168 A MX2009009168 A MX 2009009168A MX 2009009168 A MX2009009168 A MX 2009009168A MX 2009009168 A MX2009009168 A MX 2009009168A
Authority
MX
Mexico
Prior art keywords
cell
composition
helper
activation
hla
Prior art date
Application number
MX2009009168A
Other languages
English (en)
Inventor
Haruo Sugiyama
Original Assignee
Int Inst Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Inst Cancer Immunology Inc filed Critical Int Inst Cancer Immunology Inc
Publication of MX2009009168A publication Critical patent/MX2009009168A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)

Abstract

Se describe: un método para activar una célula T auxiliar, que comprende el paso de añadir un péptido WT1 a una célula presentadora de antígeno para activar la célula T auxiliar, en donde el péptido WT1 es capaz de unirse a cualquiera seleccionada de una molécula de HLA-DRB1*1501, una molécula de HLA-DPB1*0901 y una molécula de HLA-DPB1*0501; una composición para usarse en el método; un método terapéutico y/o profiláctico para cáncer al activar una célula T auxiliar; una composición farmacéutica para usarse en el método terapéutico y/o profiláctico; y otros.
MX2009009168A 2007-02-27 2008-02-27 Metodo para activacion de celula t auxiliar y composicion para usarse en el metodo. MX2009009168A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007047317 2007-02-27
PCT/JP2008/053417 WO2008105462A1 (ja) 2007-02-27 2008-02-27 ヘルパーｔ細胞の活性化方法およびそのための組成物

Publications (1)

Publication Number Publication Date
MX2009009168A true MX2009009168A (es) 2009-09-07

Family

ID=39721287

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009009168A MX2009009168A (es) 2007-02-27 2008-02-27 Metodo para activacion de celula t auxiliar y composicion para usarse en el metodo.
MX2014002596A MX352947B (es) 2007-02-27 2008-02-27 Metodo para activacion de celula t auxiliar y composicion para usarse en el metodo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014002596A MX352947B (es) 2007-02-27 2008-02-27 Metodo para activacion de celula t auxiliar y composicion para usarse en el metodo.

Country Status (25)

Country Link
US (2) US10139395B2 (es)
EP (1) EP2119778B1 (es)
JP (2) JP5225262B2 (es)
KR (1) KR101598228B1 (es)
CN (6) CN104312974B (es)
AU (1) AU2008220031B2 (es)
BR (1) BRPI0808084A2 (es)
CA (1) CA2677075C (es)
CY (1) CY1117150T1 (es)
DK (1) DK2119778T3 (es)
ES (1) ES2559062T3 (es)
HR (1) HRP20160020T1 (es)
HU (1) HUE027472T2 (es)
IL (1) IL200161A (es)
MX (2) MX2009009168A (es)
MY (2) MY158219A (es)
NZ (3) NZ599160A (es)
PL (1) PL2119778T3 (es)
PT (1) PT2119778E (es)
RU (2) RU2009135802A (es)
SG (1) SG177998A1 (es)
SI (1) SI2119778T1 (es)
UA (1) UA101608C2 (es)
WO (1) WO2008105462A1 (es)
ZA (1) ZA200905467B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2071028T3 (pl) 2003-11-05 2012-06-29 Int Inst Cancer Immunology Inc Pochodzący z WT1 peptyd antygenowy wiążący się z HLA-DR
EP2565201B1 (en) 2005-10-17 2014-11-26 Sloan-Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
EP3117836A1 (en) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and uses thereof
ES2559062T3 (es) 2007-02-27 2016-02-10 International Institute Of Cancer Immunology, Inc. Método para la activación de linfocitos T colaboradores y composición para su uso en el método
AR076349A1 (es) * 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
JP2013512694A (ja) 2009-12-08 2013-04-18 ウィルソン ウォルフ マニュファクチャリング コーポレイション 養子細胞療法のための細胞を培養する方法
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
AR083295A1 (es) * 2010-10-05 2013-02-13 Univ Osaka Metodo para activar celulas t auxiliares
EP2757373A4 (en) 2011-09-14 2015-07-01 Int Inst Cancer Immunology Inc METHOD FOR MEASURING ANTI-WT1 ANTIBODIES
EP2792745B1 (en) * 2011-12-14 2017-11-15 National University Corporation Kochi University Modification of helper t cell-inducing polypeptide
AU2013207669C1 (en) 2012-01-13 2018-05-31 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
KR20150046346A (ko) * 2012-09-12 2015-04-29 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 항원 특이적 헬퍼 t 세포 리셉터 유전자
KR102158225B1 (ko) * 2012-12-17 2020-09-21 오츠카 세이야쿠 가부시키가이샤 헬퍼 t세포의 활성화 방법
PT2945647T (pt) 2013-01-15 2020-11-26 Memorial Sloan Kettering Cancer Center Péptidos imunogénicos wt-1 e métodos de uso dos mesmos
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
EP3112378B1 (en) * 2014-02-26 2020-06-24 Tella, Inc. Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
US10695385B2 (en) 2015-06-25 2020-06-30 National University Corporation Kobe University Oral cancer vaccine
US11666646B2 (en) 2016-12-26 2023-06-06 National University Corporation Kobe University Cancer therapy utilizing combination of oral tumor vaccine and immunosuppression inhibitor
EP4085130A4 (en) 2019-12-31 2024-04-10 Elixirgen Therapeutics, Inc. TEMPERATURE-BASED TRANSIENT DELIVERY OF NUCLEIC ACIDS AND PROTEINS TO CELLS AND TISSUES
KR102647825B1 (ko) * 2021-07-22 2024-03-14 서울대학교산학협력단 항-hla-dp 단클론 항체 및 이의 용도
CN116559462A (zh) * 2023-04-12 2023-08-08 中国科学技术大学 用于肿瘤患者预后的生物标志物组及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726288A (en) 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
PT1103564E (pt) 1998-07-31 2009-03-13 Int Inst Cancer Immunology Inc Antigénios de cancro com base no produto do gene supressor de tumor wt1
BR9914116A (pt) 1998-09-30 2002-01-15 Corixa Corp Composições e métodos para imunoterapia especìfica de wt1
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
CA2401070A1 (en) 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
US20040097703A1 (en) 2001-03-22 2004-05-20 Haruo Sugiyama Wt1 modified peptide
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
ATE494905T1 (de) 2001-06-29 2011-01-15 Chugai Pharmaceutical Co Ltd Krebsimpfstoff mit einem krebs-antigen auf grundlage des produkts aus dem tumorunterdrückungsgen wt1 und einem kationischen liposom
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
WO2003028757A1 (en) 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
JPWO2003028758A1 (ja) 2001-09-28 2005-01-13 治夫 杉山 抗原特異的ｔ細胞の誘導方法
JP4365784B2 (ja) 2002-06-12 2009-11-18 株式会社癌免疫研究所 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
WO2004024175A1 (ja) 2002-09-12 2004-03-25 Haruo Sugiyama 癌抗原ペプチド製剤
EP1548028B1 (en) 2002-09-20 2009-09-09 International Institute of Cancer Immunology, Inc. Substituted type peptides of wt1
ES2332590T3 (es) 2003-01-15 2010-02-09 International Institute Of Cancer Immunology, Inc. Dimero peptidico.
KR101431312B1 (ko) 2003-06-27 2014-08-20 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ1 백신 적응 환자의 선택 방법
PL2071028T3 (pl) * 2003-11-05 2012-06-29 Int Inst Cancer Immunology Inc Pochodzący z WT1 peptyd antygenowy wiążący się z HLA-DR
CA2548135C (en) * 2003-12-01 2014-04-22 Sloan-Kettering Institute For Cancer Research Synthetic hla binding peptide analogues and uses thereof
EP2186896B1 (en) 2004-03-31 2015-11-04 International Institute of Cancer Immunology, Inc. Cancer antigen peptides derived from WT1
JP4719876B2 (ja) 2005-04-04 2011-07-06 国立大学法人愛媛大学 Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド
EP2565201B1 (en) 2005-10-17 2014-11-26 Sloan-Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
RU2424247C2 (ru) 2005-11-30 2011-07-20 Интернэшнл Инститьют Оф Кэнсер Иммьюнолоджи, Инк. Пептид, индуцирующий цитотоксические т-клетки (цтл), способ индукции цтл, антитело, связывающееся с этим пептидом, применение пептида в фармацевтической композиции и для лечения или предупреждения рака, антигенпредставляющая клетка
DK2518149T3 (en) 2006-02-22 2016-01-11 Int Inst Cancer Immunology Inc HLA-A * 3303-LIMITED WT1 PEPTIDE AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME
EP3117836A1 (en) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and uses thereof
CN101573448B (zh) 2006-12-28 2012-07-11 株式会社癌免疫研究所 Hla-a*1101限制的wt1肽及含有其的药物组合物
ES2559062T3 (es) 2007-02-27 2016-02-10 International Institute Of Cancer Immunology, Inc. Método para la activación de linfocitos T colaboradores y composición para su uso en el método
KR101669279B1 (ko) 2007-03-05 2016-10-26 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
AR083295A1 (es) 2010-10-05 2013-02-13 Univ Osaka Metodo para activar celulas t auxiliares
KR102158225B1 (ko) 2012-12-17 2020-09-21 오츠카 세이야쿠 가부시키가이샤 헬퍼 t세포의 활성화 방법

Also Published As

Publication number Publication date
CN103088103A (zh) 2013-05-08
US11555814B2 (en) 2023-01-17
RU2680539C2 (ru) 2019-02-22
CY1117150T1 (el) 2017-04-05
IL200161A0 (en) 2011-08-01
HK1138321A1 (en) 2010-08-20
CN103088103B (zh) 2015-09-30
BRPI0808084A2 (pt) 2014-07-22
MY164867A (en) 2018-01-30
RU2009135802A (ru) 2011-04-10
CN103149366B (zh) 2018-06-15
JP5225262B2 (ja) 2013-07-03
JPWO2008105462A1 (ja) 2010-06-03
CN104312974B (zh) 2018-09-04
EP2119778B1 (en) 2015-11-04
KR101598228B1 (ko) 2016-02-26
NZ599161A (en) 2012-07-27
CA2677075A1 (en) 2008-09-04
CN103103246B (zh) 2018-05-01
AU2008220031A1 (en) 2008-09-04
CA2677075C (en) 2018-07-10
CN104312974A (zh) 2015-01-28
UA101608C2 (uk) 2013-04-25
ES2559062T3 (es) 2016-02-10
CN104774910B (zh) 2018-04-10
NZ578721A (en) 2012-04-27
PL2119778T3 (pl) 2016-04-29
NZ599160A (en) 2012-07-27
KR20090125067A (ko) 2009-12-03
ZA200905467B (en) 2010-05-26
CN104774910A (zh) 2015-07-15
CN103103246A (zh) 2013-05-15
HUE027472T2 (en) 2016-09-28
US20100247556A1 (en) 2010-09-30
RU2014104572A (ru) 2015-08-20
PT2119778E (pt) 2016-02-15
EP2119778A1 (en) 2009-11-18
SI2119778T1 (sl) 2016-03-31
JP2013139448A (ja) 2013-07-18
IL200161A (en) 2015-11-30
JP5714619B2 (ja) 2015-05-07
US20200064332A1 (en) 2020-02-27
CN101622344A (zh) 2010-01-06
MY158219A (en) 2016-09-15
HRP20160020T1 (hr) 2016-02-12
US10139395B2 (en) 2018-11-27
EP2119778A4 (en) 2010-08-18
DK2119778T3 (en) 2016-01-25
SG177998A1 (en) 2012-02-28
WO2008105462A1 (ja) 2008-09-04
MX352947B (es) 2017-12-14
AU2008220031B2 (en) 2013-06-13
CN103149366A (zh) 2013-06-12

Similar Documents

Publication Publication Date Title
MX2009009168A (es) Metodo para activacion de celula t auxiliar y composicion para usarse en el metodo.
MX2018008436A (es) Metodo para activar celulas t auxiliares.
CY1114904T1 (el) Prlr-ειδικο αντισωμα και χρησεις αυτου
CL2010001475A1 (es) Compuestos derivados de ester boronato, inhibidores de proteasoma; composiciones farmaceuticas que los contienen; procedimiento de preparacion de la composición farmaceutica; utiles en el tratamiento de enfermedades proliferativas celulares, en particular cancer.
ECSP11011297A (es) Proteinas ligadoras il-17
AR088513A1 (es) Inmunoenlazantes dirigidos contra esclerostina
BRPI0905733B8 (pt) composição, formulação farmacêutica, método para a produção de uma composição farmacêutica e uso de uma formulação farmacêutica
CL2011000230A1 (es) Anticuerpo monoclonal humano aislado que se une al inhibidor de la via del factor tisular (tfpi); composicion farmaceutica que lo comprende; uso para tratar deficiencias adquiridas o geneticas de la coagulacion, o para acortar el tiempo de sangrado.
BRPI0715396B8 (pt) método de produção de uma composição para vacina
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
BRPI0906478B8 (pt) anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende
CL2011000086A1 (es) Anticuerpo aislado o proteina funcional contra el polipeptido baffr que inhibe la proliferacion de celulas b; secuencia nucleotidicas de dicho anticuerpo; vector y celula huesped que comprende dicha secuencia; y su uso para tratar enfermedades autoinmunes o neoplasias de celulas b.
AR077199A1 (es) Composicion farmaceutica y procedimiento de tratamiento para la anticoncepcion de emergencia
AR066395A1 (es) Reovirus que tienen secuencias modificadas
PH12015501361A1 (en) Method for activating helper t cell
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
ECSP088745A (es) Derivados sustituidos de cromanol y su uso
MX361778B (es) Composiciones farmaceuticas y metodos de tratamiento.
CL2009000309A1 (es) Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2.
CY1116111T1 (el) Τοπικη συνθεση για τη θεραπεια της ακτινικης κερατωσης
AR063026A1 (es) Anticuerpos dirigidos contra ccr5 y la utilizacion de los mismos
BRPI0617294B8 (pt) composição farmacêutica em gel hidroalcóolico e uso de testosterona
BR112012022243A8 (pt) Uso de um inibidor de autofagia baseado em tioxantona e de um composto indutor de autofagia para terapia de câncer, composição farmacêutica e kit farmacêutico
CL2009000665A1 (es) Compuestos derivados de pirrolidinilo; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la ansiedad, depresion o ambas.
CL2008002082A1 (es) Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades.

Legal Events

Date Code Title Description
FG Grant or registration